Jessica Shull - Vicore Pharma Head Therapeutics
| VICO Stock | SEK 10.44 1.04 11.06% |
Insider
Jessica Shull is Head Therapeutics of Vicore Pharma Holding
| Phone | 46 3 17 88 05 60 |
| Web | https://www.vicorepharma.com |
Vicore Pharma Management Efficiency
The company has return on total asset (ROA) of (0.4902) % which means that it has lost $0.4902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9886) %, meaning that it generated substantial loss on money invested by shareholders. Vicore Pharma's management efficiency ratios could be used to measure how well Vicore Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pr Mori | MTI Investment SE | 45 | |
| Erik Strmpel | COOR Service Management | 53 | |
| Andreas Engdahl | COOR Service Management | 45 | |
| Stefan Kack | JLT Mobile Computers | 68 | |
| Magnus Wikstrom | COOR Service Management | 60 | |
| sa Wirn | Scandic Hotels Group | 55 | |
| Peter Jangbratt | Scandic Hotels Group | 56 | |
| Malin | eEducation Albert AB | N/A | |
| Pontus Engstrom | MTI Investment SE | 52 | |
| Glen Shimizu | Qleanair Holding AB | N/A | |
| Sofia Nilsson | COOR Service Management | N/A | |
| Lydur Thorgeirsson | Arion banki hf | 47 | |
| Benedikt Gislason | Arion banki hf | 49 | |
| Hkon Ptursson | Arion banki hf | 42 | |
| Fredrik Wetterlundh | Scandic Hotels Group | 57 | |
| Nedim Efendic | MTI Investment SE | 45 | |
| Henrik Vikstrom | Scandic Hotels Group | N/A | |
| Styrmir Sigurjnsson | Arion banki hf | 49 | |
| Bo Niveman | MTI Investment SE | 66 | |
| Zachary Douglas | Qleanair Holding AB | N/A | |
| Arta Mandegari | eEducation Albert AB | 37 | |
Management Performance
| Return On Equity | -0.99 | |||
| Return On Asset | -0.49 |
Vicore Pharma Holding Leadership Team
Elected by the shareholders, the Vicore Pharma's board of directors comprises two types of representatives: Vicore Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vicore. The board's role is to monitor Vicore Pharma's management team and ensure that shareholders' interests are well served. Vicore Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vicore Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kicki Johansson, Chief Officer | ||
| Johan Raud, Chief Officer | ||
| Elin Rosendahl, VP Devel | ||
| Nina Carlen, Chief Officer | ||
| Asa Magnusson, Chief Officer | ||
| Rohit Batta, Chief Officer | ||
| Hans Jeppsson, Chief Officer | ||
| CarlJohan MD, Chief Officer | ||
| Jessica Shull, Head Therapeutics | ||
| Johanna Grans, Head Devel |
Vicore Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vicore Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.99 | |||
| Return On Asset | -0.49 | |||
| Current Valuation | 1.22 B | |||
| Shares Outstanding | 81.85 M | |||
| Shares Owned By Insiders | 16.14 % | |||
| Shares Owned By Institutions | 51.89 % | |||
| Price To Earning | 163.82 X | |||
| Price To Book | 8.67 X | |||
| EBITDA | (293.13 M) | |||
| Net Income | (296.48 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vicore Stock Analysis
When running Vicore Pharma's price analysis, check to measure Vicore Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicore Pharma is operating at the current time. Most of Vicore Pharma's value examination focuses on studying past and present price action to predict the probability of Vicore Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicore Pharma's price. Additionally, you may evaluate how the addition of Vicore Pharma to your portfolios can decrease your overall portfolio volatility.